FLOVENT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FLOVENT (FLOVENT).
Fluticasone propionate is a synthetic corticosteroid with anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory transcription factors (e.g., NF-κB) and increased synthesis of lipocortin-1, which reduces phospholipase A2 activity and subsequent release of arachidonic acid metabolites (prostaglandins, leukotrienes). In the lungs, it decreases airway inflammation by reducing eosinophil infiltration, mast cell degranulation, and cytokine release.
| Metabolism | Hepatic metabolism primarily via cytochrome P450 enzyme CYP3A4 to an inactive metabolite (17β-carboxylic acid derivative). First-pass metabolism is extensive, resulting in low systemic bioavailability after intranasal and inhaled administration. |
| Excretion | Primarily hepatic metabolism (CYP3A4) with fecal excretion of metabolites; renal excretion accounts for <5% of the dose as unchanged drug and metabolites combined. |
| Half-life | Approximately 14.4 hours (range 7.8–24.6 hours) for the inhaled route; supports twice-daily dosing; prolonged in hepatic impairment. |
| Protein binding | Approximately 91% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | At steady state, Vd is approximately 3.7 L/kg (range 2.0–5.6 L/kg), indicating extensive tissue distribution. |
| Bioavailability | Inhaled: Approximately 20% reaches systemic circulation (orally inhaled fluticasone propionate absolute bioavailability ~13.5% from the Diskus device); oral bioavailability is <1% due to extensive first-pass metabolism. |
| Onset of Action | Inhaled: 12–24 hours for initial bronchodilator effect; maximal improvement may require 1–2 weeks of regular use. |
| Duration of Action | Approximately 12 hours after inhalation; allows twice-daily dosing for maintenance therapy; not indicated for acute bronchospasm. |
Inhalation aerosol: 88-880 mcg twice daily; typical starting dose: 88 mcg twice daily. Max: 880 mcg twice daily. Oral inhalation powder: 100-1000 mcg twice daily; typical starting: 100 mcg twice daily. Max: 1000 mcg twice daily.
| Dosage form | POWDER |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Children 4-11 years: Inhalation aerosol 88 mcg twice daily; max 88 mcg twice daily. Children 12 years and older: same as adult dosing. |
| Geriatric use | No specific dose adjustment; use lowest effective dose due to potential for increased systemic effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FLOVENT (FLOVENT).
| Breastfeeding | Fluticasone propionate is excreted in human breast milk in trace amounts. M/P ratio not established. Inhaled doses result in low systemic bioavailability, making significant infant exposure unlikely. Use with caution, but generally considered compatible with breastfeeding. Monitor infant for signs of adrenal suppression if mother uses high doses. |
| Teratogenic Risk | Fluticasone propionate (FLOVENT) is classified as Pregnancy Category C. Inhaled corticosteroids are generally considered low risk during pregnancy. No adequate and well-controlled studies in pregnant women. Animal studies showed fetal toxicity at high systemic exposures, but inhaled use minimizes systemic absorption. First trimester: no increased risk of major congenital malformations reported in human studies. Second and third trimesters: monitor for potential fetal adrenal suppression with prolonged high-dose use, though rare. Overall, benefits typically outweigh risks for asthma control. |
■ FDA Black Box Warning
None
| Serious Effects |
Primary treatment of acute asthma attacks or status asthmaticus (not a bronchodilator). Known hypersensitivity to fluticasone propionate or any excipient. Untreated systemic infections (e.g., tuberculosis, fungal, bacterial, viral).
| Precautions | Risk of adrenal suppression, especially with higher doses or prolonged use; patients may require dose adjustment during stress. Increased risk of pneumonia in patients with COPD. Oropharyngeal candidiasis and hoarseness (local effects). Monitor for growth velocity in children. Avoid abrupt discontinuation in asthma; use with caution in patients with active or quiescent tuberculosis, ocular herpes simplex, or untreated fungal/bacterial infections. Systemic corticosteroid therapy should be tapered when transitioning to inhaled fluticasone. |
Loading safety data…
| Fetal Monitoring | Maternal: Monitor asthma symptoms, peak expiratory flow, and lung function regularly. Assess for oral candidiasis and hoarseness. Fetal: Standard prenatal monitoring including ultrasound for growth and well-being. No specific fetal monitoring required beyond routine care, but assess for possible fetal adrenal suppression with prolonged high-dose use (rare). |
| Fertility Effects | No known adverse effects on fertility in humans based on available data. Animal studies showed no impairment of fertility at inhaled doses. Asthma control itself may improve fertility outcomes by reducing hypoxia and systemic inflammation. |